Fragment-based hit identification: thinking in 3D

Andrew D. Morley; Angelo Pugliese; Kristian Birchall; Justin Bower; Paul Brennan; Nathan Brown; Tim Chapman; Martin Drysdale; Ian H. Gilbert; Swen Hoelder; Allan Jordan; Steven V. Ley; Andy Merritt; David Miller; Martin E. Swarbrick; Paul G. Wyatt

doi:10.1016/j.drudis.2013.07.011

Fragment-based hit identification: thinking in 3D

Andrew D. Morley (Lead / Corresponding author), Angelo Pugliese, Kristian Birchall, Justin Bower, Paul Brennan, Nathan Brown, Tim Chapman, Martin Drysdale, Ian H. Gilbert, Swen Hoelder, Allan Jordan, Steven V. Ley, Andy Merritt, David Miller, Martin E. Swarbrick, Paul G. Wyatt (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

144 Citations (Scopus)

Abstract

The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

Original language	English
Pages (from-to)	1221-1227
Number of pages	7
Journal	Drug Discovery Today
Volume	18
Issue number	23-24
DOIs	https://doi.org/10.1016/j.drudis.2013.07.011
Publication status	Published - Dec 2013

Access to Document

10.1016/j.drudis.2013.07.011

Cite this

@article{f99f514a6bc740729ecc25697dfd4d5e,

title = "Fragment-based hit identification: thinking in 3D",

abstract = "The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.",

author = "Morley, \{Andrew D.\} and Angelo Pugliese and Kristian Birchall and Justin Bower and Paul Brennan and Nathan Brown and Tim Chapman and Martin Drysdale and Gilbert, \{Ian H.\} and Swen Hoelder and Allan Jordan and Ley, \{Steven V.\} and Andy Merritt and David Miller and Swarbrick, \{Martin E.\} and Wyatt, \{Paul G.\}",

year = "2013",

month = dec,

doi = "10.1016/j.drudis.2013.07.011",

language = "English",

volume = "18",

pages = "1221--1227",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier",

number = "23-24",

}

TY - JOUR

T1 - Fragment-based hit identification

T2 - thinking in 3D

AU - Morley, Andrew D.

AU - Pugliese, Angelo

AU - Birchall, Kristian

AU - Bower, Justin

AU - Brennan, Paul

AU - Brown, Nathan

AU - Chapman, Tim

AU - Drysdale, Martin

AU - Gilbert, Ian H.

AU - Hoelder, Swen

AU - Jordan, Allan

AU - Ley, Steven V.

AU - Merritt, Andy

AU - Miller, David

AU - Swarbrick, Martin E.

AU - Wyatt, Paul G.

PY - 2013/12

Y1 - 2013/12

N2 - The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

AB - The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

U2 - 10.1016/j.drudis.2013.07.011

DO - 10.1016/j.drudis.2013.07.011

M3 - Article

C2 - 23906694

SN - 1359-6446

VL - 18

SP - 1221

EP - 1227

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 23-24

ER -

Fragment-based hit identification: thinking in 3D

Abstract

Access to Document

Fingerprint

Cite this